2023 Agenda


Bioprocessing Tech: Venture, Innovation, and Partnering Conference

August 16, 2023 ALL TIMES EDT

Wednesday, August 16

7:30 am

Registration Open

8:00 am

Networking Breakfast

9:00 am

Co-Chair Welcome Address

Daniella Kranjac, Founding Partner, Dynamk Capital LLC

Ann Lee, CTO, Prime Medicine, Inc.

Ran Zheng, CEO, Landmark Bio

9:10 am
SPONSORED PRESENTATION:

Recent Investment Trends in Advanced Therapeutics Modalities

Jeff Holder, PhD, Managing Director and Partner, L.E.K. Consulting

Adam Siebert

Following the unprecedented investment in life sciences over the past few years, investors are returning to pre-pandemic levels of investment, with an increasing amount invested in the next wave of ATMs. Find out how technology enablers throughout the industry are uniquely positioned to disproportionately profit from the development and commercialization of these therapies.

9:30 am
Panel One:

M&A and Strategics

PANEL MODERATOR:

Ran Zheng, CEO, Landmark Bio

  • Who is buying companies in this space?
  • Who is being acquired?
  • What do your companies look for in an acquisition or an M&A? 
  • Experiences from the frontlines of corporate/business development.
PANELISTS:

Valerie Dixon, Managing Director, Morgan Stanley

Emmanuel Ligner, President and CEO, Cytiva

Matthew Hewitt, Vice President, Technical Officer CGT & Biologics, Charles River Laboratories

Xiaoming Wang, Vice President, Business Development, Healthcare & Life Sciences, Ecolab

10:10 am
Panel Two:

Investor Panel

PANEL MODERATOR:

Daniella Kranjac, Founding Partner, Dynamk Capital LLC

Coming off a few years of the most significant growth in biotech and life sciences, but observing a significant retraction in the public and private markets: 

  • What is the current investment market like? 
  • Who is investing? Which types of organizations? 
  • What is being invested in? Thoughts on valuation, value creation, and market conditions. 
  • What can startups do to move the needle on valuation of their company? 
  • Best practices for start-ups.​
PANELISTS:

David Q. Anderson, General Partner, Ampersand Capital Partners

John Ho, Partner, Anzu Partners

Chenny Zhang, Principal, In Q Tel

Hari Pujar, Operating Partner, Flagship Pioneering; COO, Tessera Therapeutics

Murali Venkatesan, Head of Danaher Ventures, Americas & Europe; Vice President, Science, Technology & Innovation, Danaher Corporation

10:50 am

Networking Coffee Break

11:20 am

Optimizing Market Based Value for Cell & Gene Therapy (CGT) Companies through Manufacturing Options Using the Deloitte CGT Index

Amit Agarwal, Managing Director, Life Sciences, Deloitte Consulting LLP

All Cell & Gene Therapy (CGT) executive teams face critical million-dollar manufacturing decisions which are unique to this emerging field. Companies must decide between buying and retrofitting  existing manufacturing facilities, building custom manufacturing facilities, or leasing manufacturing capacity through CDMOs. Using a proprietary CGT Index, Deloitte has analyzed the quantitative impact on market value of each option over time and by type of CGT manufacturing process. This presentation will be of particular interest to executive teams, investors and CDMOs.  

11:50 am
Panel Three:

Supply Chain for CGT

PANEL MODERATOR:

Philip Vanek, CTO, Gamma Biosciences

  • Surplus inventory levels post-COVID: Is supply chain still a challenge? 
  • Consumables supply and robustness of supply chain
  • With such growth in CGT, how do we keep up?​
PANELISTS:

Heather Erickson, Vice President, Supply Chain Management & Business Operations, Sangamo

Ger Brophy, Executive Vice President, Biopharma Production, Avantor

Adam Bryan, Vice President & Head, Personalized Medicines Business Unit, Lonza, Inc.

William Beck, Director, Supply Chain, Carisma Therapeutics

Fouad Atouf, PhD, Senior Vice President, Global Biologics, USP

12:30 pm

CEO Panel

PANEL MODERATOR:

Bryan Poltilove, Advisor, BroadOak Capital Partners

  • Where is your company focused right now (financing or other)?
  • Have you adjusted your energies and approach to respond to current market challenges?
  • What are the real value drivers and differentiators for companies in a tight capital environment?
  • What has it been like fundraising at this time? 
  • What was your last raise like? 
  • What experience do you want to share about working with your investors? 
PANELISTS:

William Patrick, Co-Founder & CEO, Culture Biosciences, Inc.

Jason C. Foster, CEO and Executive Director, Ori Biotech

Alysia M Birkholz, Deputy CEO, Texcell North America Inc

Michael Keefe, CEO, Kemp Proteins

Brian Feth, CEO & Founder, Xcell Biosciences Inc

1:10 pm

Networking Luncheon

2:30 pm
Panel Four:

Accelerating Bioprocessing Innovation and Technology

PANEL MODERATOR:

Andrew Lee, Principal, Northpond Ventures

  • Trends in CGT, mRNA
  • What are the innovations being invested in beyond these areas? 
  • What needs further investment?​
PANELISTS:

Daniella Cramp, Senior Vice President and President, Bioproduction Group, Thermo Fisher Scientific

Behzad Mahdavi, Senior Vice President, Biopharma Manufacturing & Life Sciences Tools, Ginkgo Bioworks, Inc.

Paulo A Garcia, Co Founder & CEO, Kytopen Corp

Tim Kelly, CEO, RoosterBio, Inc.

Tom Ransohoff, Operating Partner, Keensight Capital

Charles Purtell, Vice President Equity Ventures, Danaher Corporation

3:10 pm
Panel Five:

CDMO & Services & Tools

PANEL MODERATOR:

Lynne B. Frick, President & CEO, Cell X Technologies, Inc.

  • How are you integrating new technology and tools into your operations? Has this changed?
  •  Which programs have companies introduced that are truly innovative?
  • The expectation for earlier and more data sharing during an engagement has increased; which strategies are companies using to cope and better serve drug development & manufacturing clients?​
PANELISTS:

Ulrike Lemke, Business Unit President, Sterile Fill & Finish, Recipharm AG

Hemanth Kaligotla, Bio R&D External Innovation, Lonza Biologics Inc

Andrew Sandford, President, ElevateBio BaseCamp

Stewart McNaull, Chief Business Officer, Wheeler Bio

3:50 pm
Plenary Keynote (Main Conference)
5:00 pm

Networking Reception (Join the Bioprocessing Summit reception in the Exhibit Hall)

6:00 pm

Close of Conference (You are welcome to visit the main conference tomorrow)